Encodes An Animal Polypeptide Patents (Class 536/23.5)
-
Publication number: 20130259924Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: March 9, 2013Publication date: October 3, 2013Applicant: MODERNA THERAPEUTICSInventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
-
Publication number: 20130261053Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.Type: ApplicationFiled: April 2, 2013Publication date: October 3, 2013Applicants: ServicesInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130259923Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: March 9, 2013Publication date: October 3, 2013Applicant: MODERNA THERAPEUTICSInventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
-
Publication number: 20130261060Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.Type: ApplicationFiled: June 4, 2013Publication date: October 3, 2013Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
-
Patent number: 8546347Abstract: The present invention relates to a composition for the treatment and improvement of diabetes comprising caveolin as an active ingredient and a method for treating diabetes using the same, more precisely a composition comprising caveolin-1 as an active ingredient for the treatment and improvement of type II diabetes which is age-dependent but not showing obesity symptom and a method for treating diabetes using the same. The treatment method and composition of the present invention is very effective in improving and treating diabetes by regulating insulin sensitivity by increasing caveolin level in muscle tissues of type II diabetes patient which is age-dependent but not showing obesity symptom.Type: GrantFiled: March 21, 2008Date of Patent: October 1, 2013Assignee: Seoul National University Industry FoundationInventors: Sang Chul Park, Yoon Sin Oh
-
Publication number: 20130253040Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.Type: ApplicationFiled: February 28, 2013Publication date: September 26, 2013Applicant: C/O SANGAMO BIOSCIENCES, INC.Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
-
Publication number: 20130251751Abstract: The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample of tumorous and corresponding healthy tissue is first provided, the tumor-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analyzed. The respective data that has been obtained is then matched and peptides are identified on the basis of said data.Type: ApplicationFiled: February 22, 2013Publication date: September 26, 2013Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni WEINSCHENK, Hans Georg RAMMENSEE
-
Publication number: 20130254908Abstract: MO-1 is a newly identified gene and gene product associated with morbid obesity. Isolated MO-1 nucleic acids, MO-1 polypeptides, oligonucleotides that hybridize to MO-1 nucleic acids, and vectors, including expression vectors, comprising MO-1 nucleic acids are disclosed, as are isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to MO-1. Methods of detecting the presence of MO-1 nucleic acid, methods of screening for agents which affect MO-1 activity, and methods of screening for MO-1 variants are also disclosed.Type: ApplicationFiled: October 12, 2012Publication date: September 26, 2013Applicant: MOUNT SINAI SCHOOL OF MEDICINEInventors: Adel Shalata, John Martignetti, Robert Desnick
-
Patent number: 8541202Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.Type: GrantFiled: February 24, 2012Date of Patent: September 24, 2013Assignee: Ludwig Institute for Cancer ResearchInventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
-
Patent number: 8541564Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.Type: GrantFiled: May 25, 2012Date of Patent: September 24, 2013Assignee: Morehouse School of MedicineInventor: James W. Lillard, Jr.
-
Publication number: 20130244955Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: August 16, 2011Publication date: September 19, 2013Inventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba
-
Publication number: 20130245238Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.Type: ApplicationFiled: February 1, 2013Publication date: September 19, 2013Inventors: Jonathan DAVIS, Dasa Lipovsek, Ray Camphausen
-
Publication number: 20130243755Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SED ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.Type: ApplicationFiled: January 15, 2013Publication date: September 19, 2013Applicant: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)Inventor: Institut National De La Santa Et De La Recherche Medicale (INSERM)
-
Publication number: 20130243796Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20130245103Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.Type: ApplicationFiled: May 18, 2013Publication date: September 19, 2013Applicant: Moderna TherapeuticsInventors: Antonin de Fougerolles, Sayda M. Elbashir, Jason P. Schrum
-
Publication number: 20130243821Abstract: The present invention includes novel soybean derived human thyroglobulin, methods of producing human thyroglobulin in plants such as soybean, and novel diagnostic applications for the detection and stratification of endocrine malignancies including thyroid cancer and thyroiditis. The invention also includes the use of soybean-derived human thyroglobulin in affinity matrices to remove autoreactive anti-thyroglobulin antibodies from patient's sera prior to analyses. Moreover, the invention also includes methods and compositons of treating, preventing and or/ameliorating symptoms associated with thyroiditis.Type: ApplicationFiled: September 2, 2011Publication date: September 19, 2013Inventors: Kenneth John Piller, Kenneth Lee Bost
-
Publication number: 20130247233Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: OMEROS CORPORATIONInventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Publication number: 20130243802Abstract: The present application is directed to a peptides comprising an a-helix forming-amino acid sequence that binds a heat shock protein. Also included is a polypeptide comprising (a) a first peptide portion that comprises an ?-helix-forming amino acid sequence that binds a heat shock protein; and (b) at least one second peptide portion comprising an antigenic amino acid sequence and/or an a-helix-stabilizing amino acid sequence that increases the interaction of the first peptide portion with the heat shock protein. The present application also includes compositions comprising the peptides and/or polypeptides of present application and uses of the peptides and/or polypeptides of the present application for fractionating substances relevant for discovery, research or clinical analysis from a biological sample and as therapeutics.Type: ApplicationFiled: March 21, 2012Publication date: September 19, 2013Applicant: Atlantic Research Center InstituteInventors: Steven Gareth Griffiths, Scott Edwin Lewis
-
Publication number: 20130245228Abstract: The present invention relates to a method of in vitro isolation of buffalo ?-caesin promoter (buCSN2) along with the regions exon1, intron1 and exon2 from the genomic DNA in vitro (Bubalus bubalis) and its functional activity in using mammary cell line. The novel buffalo ?-caesin promoter along with exon1, intron1 and exon2 is isolated and cloned upstream of the Enhanced Green flourescence protein (EGFP) gene and sequenced. The transfection of the DNA construct resulted into production of EGFP protein in mammary cell lines, confirming bioactivity of this newly isolated buffalo promoter sequence. More specifically, the present invention relates to isolation, cloning, sequencing and functional analysis of the buffalo ?-casein promoter in vitro using mammary cell line.Type: ApplicationFiled: May 20, 2013Publication date: September 19, 2013Applicant: National Institute of ImmunologyInventors: Subeer Suhash Majumdar, Nirmalya Ganguli, Abul Usmani
-
Publication number: 20130243799Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: ApplicationFiled: January 25, 2013Publication date: September 19, 2013Applicant: VIVENTIA BIOTECHNOLOGIES INC.Inventors: Francina C. CHAHAL, Glen MACDONALD, Jeannick CIZEAU
-
Publication number: 20130237475Abstract: The present invention pertains to the field of production of recombinant proteins, using a synthetic gene for increased expression of the protein in Pichia pastoris. More specifically, the invention describes the production of a recombinant Sm14 protein of Schistosoma mansoni, by providing a synthetic gene for increased production of Sm14 protein, producing said gene and genetically manipulating the Pichia pastoris strain with said gene in order to produce a vaccine effectively. Improved methods are also provided for producing and purifying this protein from P. pastoris cells, which can be scaled for industrial production.Type: ApplicationFiled: September 13, 2011Publication date: September 12, 2013Applicants: ALVOS - CONSULTORIA, DESENVOLVIMENTO E COMERCIALIZAÇÃO DE PRODUTOS BIOTECNOLÓGICOS S/A, FUNDAÇÃO OSWALDO CRUZInventors: Miriam Tendler, Celso Raul Romero Ramos, Andrew J.G. Simpson
-
Publication number: 20130236959Abstract: Thermostable FGF-2 proteins having enhanced ability to support human pluripotent stem cell cultures are provided. Also provided are methods and compositions utilizing thermostable FGF-2 proteins.Type: ApplicationFiled: December 17, 2012Publication date: September 12, 2013Inventors: Guokai Chen, James A. Thomson, Zhonggang Hou
-
Publication number: 20130237472Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof.Type: ApplicationFiled: September 7, 2011Publication date: September 12, 2013Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Publication number: 20130230855Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.Type: ApplicationFiled: April 19, 2013Publication date: September 5, 2013Applicant: Merck Sharp & Dohme Corp.Inventors: ELIZABETH BATES, NATHALIE FOURNIER, LIONEL CHALUS, PIERRE GARRONE
-
Publication number: 20130230532Abstract: The present invention provides a novel myomegalin isoform—myomegalin variant 8 (MMG8). The myomegalin variant 8 regulates microtubule organization at the Golgi apparatus, protein modification, secretion and trafficking, and cell proliferation. The present invention also provides nucleic acid molecules encoding the myomegalin isoforms, and vectors and host cells containing the nucleic acid molecules. Also provided are fusion constructs comprising the myomegalin isoform and antibodies that bind specifically to the myomegalin isoforms of the present invention. The present invention further provides uses of the myomegalin isoform as a diagnostic biomarker and as a target for screening for therapeutics for diseases such as cancer, diabetes, and lysosomal storage diseases.Type: ApplicationFiled: November 15, 2011Publication date: September 5, 2013Applicant: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Zhe Wang, Robert Zhong QI
-
Publication number: 20130230849Abstract: The present invention provides an isolated nucleic acid molecule containing a repeat region of an isolated spinocerebellar ataxia type 8 (SCA8) coding sequence, the coding sequence located within the long arm of chromosome 13, and the complement of the nucleic acid molecule. Diagnostic methods based on identification of this repeat region are also provided.Type: ApplicationFiled: August 20, 2012Publication date: September 5, 2013Applicant: Regents of the University of MinnesotaInventors: Laura P. W. Ranum, Michael D. Koob, Kellie A. Benzow, Melinda L. Moseley-Alldredge
-
Publication number: 20130232588Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: September 14, 2012Publication date: September 5, 2013Applicant: Intrexon CorporationInventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
-
Publication number: 20130230918Abstract: Novel collectin related molecules i.e., a novel collectin gene comprising a nucleotide sequence set out in SEQ ID NO: 1, and a novel collectin comprising an amino acid sequence set out in SEQ ID NO: 2, which are expected to exhibit anti-bacterial, anti-viral activity or the like especially in human body, and methods in which these molecules are used are provided.Type: ApplicationFiled: February 10, 2012Publication date: September 5, 2013Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Nobutaka Wakamiya
-
Publication number: 20130230852Abstract: The present disclosure provides methods and compositions for diagnosis and for providing a prognosis of a cancer patient by assessing CK2 alpha 1 pseudogene (CSNK2A1P) status. The present disclosure also provides polypeptide, polynucleotide, host cell, and transgenic animal compositions associated with CSNK2A1P.Type: ApplicationFiled: July 1, 2011Publication date: September 5, 2013Applicant: The Regents of the University of CaliforniaInventors: Liang You, Zhidong Xu, Biao He, David Jablons
-
Patent number: 8524678Abstract: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.Type: GrantFiled: May 26, 2006Date of Patent: September 3, 2013Assignee: The Regents of the University of Colorado, a body corporateInventors: Linda May Rothblum Watkins, Travis Hughes, Raymond A. Chavez
-
Patent number: 8524491Abstract: Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.Type: GrantFiled: September 4, 2009Date of Patent: September 3, 2013Assignee: University of Washington through its Center for CommercializationInventors: Martin A Cheever, Mary L Disis
-
Publication number: 20130225500Abstract: The present invention provides an active peptide purified from scorpions, and derivatives, analogues and active fragment which are produced by using genetic engineering technology. The analgesic active peptide VGG is extracted, separated and purified from scorpion, and its amino acid sequence is shown as below: VKDGYIADDRNCPYFCGRNAYCDGECKKNRAESGYCQWASKYGNACWCY KLPDDARIMKPGRCNGG. The present invention further provides a use of the peptides in preparation of an analgesic drug, where the peptide is mixed with a pharmaceutically acceptable carrier to prepare into forms for injection, oral administration, transdermal absorption, and transmucosal absorption.Type: ApplicationFiled: July 5, 2011Publication date: August 29, 2013Applicant: SHENYANG PHARMACEUTICAL UNIVERSITYInventors: Jianhai Zhang, Zhou Yang, Yanfeng Liu, Chunfu Wu
-
Publication number: 20130225508Abstract: The present invention relates to a peptide capable of binding to an immunoglobulin, and to a fusion protein containing such a peptide. The present invention also relates to a pharmaceutical composition for the treatment or prevention of a disease caused by binding between C1q and an immunoglobulin, which comprises a peptide capable of binding to the immunoglobulin or a fusion protein with such a peptide, and to the like. The pharmaceutical composition provided by the present invention is effective particularly in treating arthritis and rheumatism.Type: ApplicationFiled: September 22, 2011Publication date: August 29, 2013Inventors: Osamu Masaki, Tetsuya Tomita
-
Publication number: 20130225484Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: AMGENInventor: AMGEN
-
Publication number: 20130225496Abstract: The invention relates to variants of albumin. The invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of preparing the variants and to methods of using the variants.Type: ApplicationFiled: November 1, 2011Publication date: August 29, 2013Applicant: Novozymes Biopharma DK A/SInventors: Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20130225490Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: ApplicationFiled: May 6, 2013Publication date: August 29, 2013Applicant: IMMUNEX CORPORATIONInventors: John Ernest Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
-
Publication number: 20130225795Abstract: The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.Type: ApplicationFiled: December 23, 2010Publication date: August 29, 2013Inventors: Christoph Schmidt, Paul N. Barlow, Anna Richards
-
Publication number: 20130225436Abstract: The present disclosure provides a method of producing enzyme-specific inhibitors or substrate binding partners comprising: identifying active site residues of the substrate in the enzyme substrate complex or in substrate binding partner-substrate complex; randomizing the active site residues to produce a combinatorial library of substrate variants; and selecting substrate variants that inhibit enzyme activity or bind substrate as substrate-specific binding partners. The present disclosure also provides ubiquitin enzyme specific inhibitors and ubiquitin variants that bind ubiquitin interaction motifs.Type: ApplicationFiled: June 8, 2011Publication date: August 29, 2013Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Sachdev Sidhu, Linda Beatty, Andreas Ernst
-
Publication number: 20130225547Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.Type: ApplicationFiled: April 29, 2013Publication date: August 29, 2013Applicant: Yeda Research and Development Co., Ltd.Inventor: Yeda Research and Development Co. Ltd.
-
Publication number: 20130225478Abstract: Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.Type: ApplicationFiled: July 19, 2011Publication date: August 29, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yechiel Shai, Avner Fink, Eliran-Moshe Reuven, Liraz Shmuel-Galia
-
Publication number: 20130224313Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: May 31, 2011Publication date: August 29, 2013Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Publication number: 20130224285Abstract: The present invention presents new insights in the mechanism of action of the estrogen receptor alpha in breast cancer cells and provides means and tools for modulating said mechanisms of action, thereby influencing the proliferation of estrogen-positive cells such as cancer cells.Type: ApplicationFiled: October 13, 2011Publication date: August 29, 2013Applicants: Universite Libre de Buxelles, UNIVERSITE PIERRE ET MARIE CURIE - UPMC, CNRS, UNIVERSITY OF CRETE - SCHOOL OF MEDICINEInventors: Dominique Gallo, Guy LeClercq, Iman Haddad, Joelle Vinh, Elias Castanas, Marilena Kampa, Vasiliki Pelekanou, Yves Jacquot
-
Publication number: 20130224234Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTLL4 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from TTLL4 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTLL4, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: ApplicationFiled: September 6, 2011Publication date: August 29, 2013Applicant: Onco Therapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa
-
Publication number: 20130225493Abstract: The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.Type: ApplicationFiled: March 21, 2013Publication date: August 29, 2013Inventors: Avner Yayon, Eran Rom, Roy Sirkis, Dalit Strauss-Ayali
-
Patent number: 8519101Abstract: Disclosed are a protein encoded by any one of nucleic acids (i) to (iv): (i) a nucleic acid having a base sequence of SEQ ID NO: 1; (ii) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2; (iii) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (i); (iv) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (i) under stringent conditions, and a silk thread containing the protein.Type: GrantFiled: February 11, 2013Date of Patent: August 27, 2013Assignee: Okamoto CorporationInventors: Tianfu Zhao, Masao Nakagaki
-
Patent number: 8518695Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.Type: GrantFiled: January 11, 2012Date of Patent: August 27, 2013Assignees: Novartis AG, Universite de StrasbourgInventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
-
Publication number: 20130219532Abstract: The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes, such as protecting plants from fungal infections; treating fungal infections of animals, especially humans; and prevention of food spoilage.Type: ApplicationFiled: March 27, 2013Publication date: August 22, 2013Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Peter David East, Susan Elizabeth Brown
-
Publication number: 20130216579Abstract: Disclosed herein are methods and compositions for genome editing of the malarial parasite Plasmodium, and for the use of the edited Plasmodium in the development of vaccines and therapeutics.Type: ApplicationFiled: January 23, 2013Publication date: August 22, 2013Applicants: The Trustees of Columbia University in the City of New York, Sangamo BioSciences, Inc.Inventors: Sangamo BioSciences, Inc., The Trustees of Columbia University in the City of New York
-
Publication number: 20130216563Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.Type: ApplicationFiled: August 1, 2012Publication date: August 22, 2013Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
-
Publication number: 20130217637Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: November 21, 2012Publication date: August 22, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventor: The Trustees of Columbia University in the City of